Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 0.91% as of August 20, 2025, with mixed performance among constituent stocks [1] - Heartbeat Medical led the gains with an increase of 3.13%, while Yuandong Biological experienced the largest decline [1] - The market for the Sci-Tech Medical ETF managed by Harvest saw a turnover rate of 24.05% and a transaction volume of 62.637 million yuan, indicating active trading [3] Group 2 - The latest scale of the Sci-Tech Medical ETF reached 263 million yuan, marking a one-month high and ranking first among comparable funds [3] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 6.157 million yuan, totaling 15.2382 million yuan [3] - The net value of the ETF increased by 56.59% over the past year, with the highest monthly return since inception being 23.29% [3] Group 3 - The total amount of business cooperation for innovative drugs in China is projected to reach 51.9 billion USD in 2024, with a record 1.25 billion USD upfront payment transaction between 3SBio and Pfizer in 2025 [4] - The Chinese innovative drug sector has seen a 25.02% increase year-to-date, ranking fourth among 31 industries, with a current PE ratio of 31.31 times [4] - The National Healthcare Security Administration has introduced a temporary management method for disease-based payment, promoting payment reform in the healthcare sector [4] Group 4 - As of July 31, 2025, the top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index accounted for 49.14% of the index, with leading companies including United Imaging and BeiGene [4][6] - The performance of individual stocks varied, with United Imaging down by 0.26% and BeiGene up by 0.95% [6] - Investors without stock accounts can access the Sci-Tech Medical ETF through the Harvest Sci-Tech Medical ETF linked fund [6]

Group 1 - The core viewpoint of the news highlights the recent trading performance of Junshi Biosciences, indicating a decline in stock price and significant trading volume on August 19, with a net financing purchase of 2671.81 million yuan [1] - As of August 19, the total margin balance for Junshi Biosciences reached 12.45 billion yuan, with a financing balance of 12.35 billion yuan, accounting for 3.56% of the circulating market value, which is above the 90th percentile of the past year [1] - The short selling activity on August 19 included a repayment of 2902 shares and a sale of 3400 shares, with a total selling amount of 15.41 million yuan, indicating a high short selling balance of 988.27 million yuan, exceeding the 80th percentile of the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 84.18% of its revenue coming from drug sales [2] - For the first quarter of 2025, Junshi Biosciences reported a revenue of 5.01 billion yuan, reflecting a year-on-year growth of 31.46%, while the net profit attributable to shareholders was -2.35 billion yuan, showing a year-on-year increase of 17.01% [2] - As of March 31, 2025, the top ten circulating shareholders of Junshi Biosciences included various ETFs, with notable reductions in holdings by some funds, while Hong Kong Central Clearing Limited increased its holdings [3]

Group 1 - The majority of Hong Kong biotech stocks experienced declines, with notable drops in several companies [1] - Specifically, Gilead Sciences fell by 15.06%, while Yunkang Group and Pigeon BioPharma dropped over 14% and 9% respectively [2] - Other companies such as China Antibody and Jiahua Bio also saw declines exceeding 7% [1][2] Group 2 - The latest market prices and total market capitalizations for the affected companies include: - Gilead Sciences at 15.510 with a market cap of 14.946 billion - Yunkang Group at 2.300 with a market cap of 1.429 billion - Pigeon BioPharma at 31.760 with a market cap of 12.258 billion - Tengsheng BioPharma at 2.210 with a market cap of 1.590 billion - China Antibody at 3.210 with a market cap of 4.371 billion - Jiahua Bio at 4.460 with a market cap of 2.347 billion [2]

Summary of Key Points Core Viewpoint - The Hong Kong biotechnology sector experienced a significant decline, with most stocks falling sharply, indicating a bearish trend in the market [1]. Company Performance - **Gilead Sciences (歌礼制药-B)**: Decreased by 15.06%, latest price at 15.510, market cap at 14.946 billion [2]. - **Yunkang Group (云康集团)**: Fell by 14.18%, latest price at 2.300, market cap at 1.429 billion [2]. - **PAG Pharmaceuticals (派格生物医药-B)**: Dropped by 9.15%, latest price at 31.760, market cap at 12.258 billion [2]. - **Tengsheng Boao (腾盛博药-B)**: Declined by 8.30%, latest price at 2.210, market cap at 1.590 billion [2]. - **China Antibody (中国抗体-B)**: Decreased by 7.49%, latest price at 3.210, market cap at 4.371 billion [2]. - **Jiahua Biotech (嘉和生物-B)**: Fell by 7.08%, latest price at 4.460, market cap at 2.347 billion [2]. - **Sillod Pharmaceuticals (思路迪医药股份)**: Dropped by 6.06%, latest price at 7.910, market cap at 2.042 billion [2]. - **Tiger Med (泰格医药)**: Decreased by 5.73%, latest price at 54.250, market cap at 46.711 billion [2]. - **Kangji Medical (加科思-B)**: Fell by 5.69%, latest price at 8.120, market cap at 6.404 billion [2]. - **WuXi AppTec (药明巨诺-B)**: Dropped by 5.14%, latest price at 5.720, market cap at 2.382 billion [2]. - **Three Leaf Clover Biotech (三叶草生物-B)**: Decreased by 5.13%, latest price at 0.740, market cap at 0.960 billion [2]. - **Yiming Oncology (宜明昂科-B)**: Fell by 4.76%, latest price at 12.810, market cap at 5.218 billion [2]. - **Junshi Biosciences (君实生物)**: Decreased by 4.69%, latest price at 34.540, market cap at 35.462 billion [2]. - **Zhonghui Biotech (中慧生物-B)**: Fell by 4.39%, latest price at 51.150, market cap at 20.125 billion [2]. - **Zhaoyan New Drug (昭衍新药)**: Decreased by 4.38%, latest price at 23.140, market cap at 17.343 billion [2].

资料显示，上海君实生物医药科技股份有限公司位于上海市浦东新区平家桥路100弄6号7幢16层,香港铜 锣湾希慎道33号利园1期19楼1918室，成立日期2012年12月27日，上市日期2020年7月15日，公司主营业 务涉及单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术 转让等。主营业务收入构成为：药品销售84.18%，技术许可及特许权使用收入12.08%，其他(补 充)3.73%。 截至3月31日，君实生物股东户数2.94万，较上期增加0.24%；人均流通股25987股，较上期减少0.23%。 2025年1月-3月，君实生物实现营业收入5.01亿元，同比增长31.46%；归母净利润-2.35亿元，同比增长 17.01%。 机构持仓方面，截止2025年3月31日，君实生物十大流通股东中，华夏上证科创板50成份ETF （588000）位居第六大流通股东，持股3025.34万股，相比上期减少505.06万股。易方达上证科创板 50ETF（588080）位居第八大流通股东，持股2158.33万股，相比上期减少86.92万股。香港中央结算有 限公司位居第九大流通股东，持股1499. ...

君实生物(01877)再涨超18%，截至发稿，涨13.75%，报36.4港元，成交额8.09亿港元。 本文源自：智通财经网 消息面上，近日，君实生物宣布，国家药品监督管理局已于近日受理公司自主研发的抗PD-1单抗药物 特瑞普利单抗合荣昌生物(09995)自主研发的抗体偶联(ADC)药物维迪西妥单抗用于HER2表达的局部晚 期或转移性尿路上皮癌患者的新适应症上市申请获得受理。据悉，这是特瑞普利单抗在中国内地递交的 第十三项适应症上市申请。 长江证券认为，君实生物是国内最早一批成立的创新药Biotech公司，特瑞普利单抗是中国最早获批的 PD-1单抗。当前时间节点来看，君实生物存量业务迎来销售提速，此外创新资产即将密集进入III期临 床阶段、多个重磅资产亟需价值重估，早研平台和资产储备完备，公司基本面拐点已现。 ...

Group 1 - The Xinhua 500 Index (989001) closed at 4668.98 points on August 18, with an increase of 0.95% [1][4] - The index opened higher in the morning, experienced a slight pullback for gap filling, and then rose significantly before narrowing its gains in the afternoon [3] - The index reached a high of 4704.83 points and a low of 4625.92 points during the trading day, with a total trading volume of 893.2 billion yuan, which was an increase compared to the previous trading day [3] Group 2 - Notable gainers among constituent stocks included Mango Super Media, which rose by 16.98%, Junshi Biosciences by 12.05%, and Tonghuashun by 10.27%, with several stocks reaching approximately 10% limit up [3] - Conversely, stocks such as Bank of China Securities, Siyuan Electric, and CITIC Special Steel experienced significant declines [3]

Core Viewpoint - Junshi Biosciences (01877) has seen a significant stock increase of over 18%, currently trading at 36.4 HKD with a transaction volume of 809 million HKD, following the acceptance of new drug applications by the National Medical Products Administration for its PD-1 monoclonal antibody and an ADC drug for specific cancer indications [1] Group 1 - Junshi Biosciences announced that the National Medical Products Administration has accepted its application for the PD-1 monoclonal antibody, Toripalimab, and the ADC drug, Vidisirtan, for new indications in treating locally advanced or metastatic urothelial carcinoma [1] - This marks the thirteenth indication application for Toripalimab submitted in mainland China [1] - Changjiang Securities views Junshi Biosciences as one of the earliest innovative biotech companies in China, with Toripalimab being the first PD-1 monoclonal antibody approved in the country [1] Group 2 - The current timing indicates that Junshi Biosciences is experiencing accelerated sales in its existing business, with innovative assets set to enter Phase III clinical trials [1] - Several significant assets are due for value reassessment, and the company has a well-established early research platform and asset reserve [1] - The fundamental turning point for the company is becoming evident [1]

Core Viewpoint - Junshi Biosciences (01877) has seen a significant stock increase of over 18%, currently trading at 36.4 HKD with a transaction volume of 809 million HKD, following the acceptance of new drug applications by the National Medical Products Administration for its PD-1 monoclonal antibody, Toripalimab, and an ADC drug, Vidutolimab, for new indications in cancer treatment [1][1]. Group 1 - Junshi Biosciences announced that the National Medical Products Administration has accepted its application for Toripalimab and Vidutolimab for new indications in treating locally advanced or metastatic urothelial carcinoma patients [1][1]. - This marks the thirteenth indication application for Toripalimab submitted in mainland China [1][1]. - Changjiang Securities views Junshi Biosciences as one of the earliest innovative biotech companies in China, with Toripalimab being the first PD-1 monoclonal antibody approved in the country [1][1]. Group 2 - The current timing indicates that Junshi Biosciences is experiencing accelerated sales in its existing business, with innovative assets set to enter Phase III clinical trials soon [1][1]. - Several significant assets are in need of value reassessment, and the company has a well-established early research platform and asset reserve [1][1]. - The fundamental turning point for the company is becoming evident [1][1].

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating which companies saw the largest increases and decreases in ownership percentages. Group 1: Companies with Increased Holdings - Zhengzhou Bank (06196) saw the largest increase in holdings, up by 2.16% to a total holding of 53.89% [1][2] - Kanglong Chemical (03759) increased by 1.35%, reaching a holding of 56.80% [1][2] - Weimob Group (02013) rose by 1.22%, with a current holding of 32.63% [1][2] - Other notable increases include Longi Green Energy (06869) at +1.00% (56.28%) and Junshi Biosciences (01877) at +0.87% (55.48%) [2][3] Group 2: Companies with Decreased Holdings - Heng Seng China Enterprises (02828) experienced the largest decrease, down by 8.07% to a holding of 0.85% [1][2] - The Yingfu Fund (02800) decreased by 4.21%, now at 0.68% [1][2] - Delin Holdings (01709) saw a reduction of 3.04%, with a holding of 23.31% [1][2] - Other significant decreases include Kylin Holdings (06821) at -4.76% (46.29%) and Dongyang Sunshine Pharmaceutical (06887) at -4.22% (48.82%) [3][4] Group 3: Five-Day Changes - Longi Green Energy (06869) had the highest five-day increase at +5.78%, with a holding of 56.28% [3][4] - Delin Holdings (01709) increased by 4.74% to 23.31% [3][4] - Lens Technology (06613) rose by 3.84%, reaching 5.97% [3][4] Group 4: Twenty-Day Changes - Longi Green Energy (06869) also led in the twenty-day increase with +25.78%, holding 56.28% [4] - Other notable increases include Dongfang Electric (01072) at +11.23% (38.53%) and China Energy Construction (03996) at +10.76% (20.18%) [4]